Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2281 to 2295 of 7785 results

  1. Guselkumab for previously treated moderately to severely active Crohn's disease ID6238

    In development [GID-TA11245] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]

    In development [GID-TA11587] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  3. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]

    In development [GID-TA11408] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Non-alcoholic fatty liver disease (NAFLD): assessment and management

    In development [GID-NG10434] Expected publication date: TBC

    NICE guideline
    In development

  5. Natural Cycles for monitoring fertility

      Status ...

    Medical technologies guidance
    Topic selection

  6. Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423

    In development [GID-TA11431] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  7. Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma PD [ID6527]

    Awaiting development [GID-TA11653] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Insertion of a Catheter based intravascular microaxial blood pump for acute heart failure

    Awaiting development [GID-IPG10404] Expected publication date: 11 March 2026

    Interventional procedures guidance
    Awaiting development

  9. Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]

    Awaiting development [GID-TA11088] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Lomitapide for treating homozygous familial hypercholesterolaemia in people 5 to 17 years [TSID 12085]

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [TSID11991]

    Awaiting development [GID-TA11518] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 [TSID11848]

      Status ...

    Technology appraisal guidance
    Topic selection

  13. Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]

    In development [GID-TA11233] Expected publication date: 04 June 2025

    Technology appraisal guidance
    In development

  14. Fruquintinib for previously treated metastatic colorectal cancer ID6274

    In development [GID-TA11280] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]

    Awaiting development [GID-TA11457] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development